Van ECK Associates Corp Sells 224,170 Shares of Elanco Animal Health Incorporated $ELAN

by · The Markets Daily

Van ECK Associates Corp cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 24.1% in the second quarter, Holdings Channel reports. The fund owned 707,194 shares of the company’s stock after selling 224,170 shares during the quarter. Van ECK Associates Corp’s holdings in Elanco Animal Health were worth $17,404,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ELAN. BlackRock Inc. purchased a new position in Elanco Animal Health during the second quarter valued at approximately $1,202,198,000. Peak Retirement Planning Inc. purchased a new stake in Elanco Animal Health during the fourth quarter worth $2,756,000. Norges Bank bought a new stake in Elanco Animal Health during the 4th quarter valued at $32,415,000. Sei Investments Co. boosted its position in Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after acquiring an additional 4,975,721 shares in the last quarter. Finally, S&CO Inc. purchased a new position in shares of Elanco Animal Health in the 2nd quarter valued at $2,738,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

ELAN has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Morgan Stanley increased their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. UBS Group raised their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 20th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus target price of $29.09.

View Our Latest Research Report on ELAN

Insiders Place Their Bets

In other Elanco Animal Health news, insider Shiv O’neill purchased 3,998 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider directly owned 87,832 shares in the company, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael J. Harrington purchased 5,000 shares of Elanco Animal Health stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $21.82 per share, with a total value of $109,100.00. Following the acquisition, the director directly owned 131,451 shares in the company, valued at $2,868,260.82. This trade represents a 3.95% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 63,198 shares of company stock valued at $1,473,109. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $24.16 on Monday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The stock has a market capitalization of $12.07 billion, a price-to-earnings ratio of -58.93, a PEG ratio of 1.44 and a beta of 1.67. The firm’s 50 day simple moving average is $24.62 and its 200-day simple moving average is $24.00. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

See Also

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).